P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
Titel:
P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure
Auteur:
Poordad, Fred Pol, Stanislas Asatryan, Armen Buti, Maria Shaw, David Hézode, Christophe Felizarta, Franco Reindollar, Robert W. Gordon, Stuart C. Pianko, Stephen Fried, Michael W. Bernstein, David E. Gallant, Joel Lin, Chih-Wei Lei, Yang Ng, Teresa I. Pilot-Matias, Tami Kort, Jens Mensa, Federico